Analysts expect Ani Pharmaceuticals Inc to report revenue of 285.00 M for Q4 26, against a range of 268.89 M to 301.10 M. The most recent reported quarter, Q3 26, came in at 290.78 M, a 1.2% miss against the 294.41 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 190.57 M | 197.12 M | 211.37 M | 227.81 M | 247.06 M | 237.46 M | 266.04 M | 290.78 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 174.56 M | 205.07 M | 193.29 M | 244.75 M | 235.06 M | 213.97 M | 294.51 M | 306.24 M | 301.10 M | 286.76 M | 297.27 M | 316.36 M | 358.35 M | 327.15 M | 339.54 M | 397.57 M | |||||||||
| Low Estimate | 156.82 M | 172.63 M | 165.91 M | 200.30 M | 213.36 M | 181.87 M | 252.51 M | 282.58 M | 268.89 M | 254.48 M | 278.91 M | 296.80 M | 300.69 M | 271.69 M | 307.39 M | 329.31 M | |||||||||
| Consensus Estimate | 165.69 M | 188.85 M | 179.60 M | 222.52 M | 224.21 M | 197.92 M | 273.51 M | 294.41 M | 285.00 M | 270.62 M | 288.09 M | 306.58 M | 329.52 M | 299.42 M | 323.46 M | 363.44 M |
Analysts expect Ani Pharmaceuticals Inc to report earnings per share of 2.76 for Q4 26, against a range of 2.56 to 2.96. The most recent reported quarter, Q3 26, came in at 2.70, a 26.8% beat against the 2.13 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.63 | 1.70 | 1.80 | 2.04 | 2.33 | 2.05 | 2.21 | 2.70 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 1.62 | 1.42 | 1.50 | 1.81 | 2.06 | 1.47 | 2.10 | 2.31 | 2.96 | 1.73 | 2.43 | 3.19 | 3.30 | 2.46 | 2.90 | 3.37 | |||||||||
| Low Estimate | 1.36 | 1.18 | 1.38 | 1.49 | 1.84 | 1.23 | 1.74 | 1.95 | 2.56 | 1.55 | 2.11 | 2.81 | 2.78 | 2.12 | 2.64 | 2.81 | |||||||||
| Consensus Estimate | 1.49 | 1.30 | 1.44 | 1.65 | 1.95 | 1.35 | 1.92 | 2.13 | 2.76 | 1.64 | 2.27 | 3.00 | 3.04 | 2.29 | 2.77 | 3.09 |
Pull Wall Street consensus for Ani Pharmaceuticals Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ANIP&mode=revenue&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ANIP", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/estimates?ticker=ANIP&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();